Currently out of the existing stock ratings of David Lebowitz, 94 are a BUY (59.87%), 38 are a HOLD (24.2%), 25 are a SELL (15.92%).

David Lebowitz

Work Performance Price Targets & Ratings Chart

Analyst David Lebowitz works at CITI with a stock forecast success ratio of 50.3% fulfilled within 145.38 days on average.

David Lebowitz’s has documented 300 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 10-May-2024.

Wall Street Analyst David Lebowitz

Analyst best performing recommendations are on SDGR (SCHRODINGER).
The best stock recommendation documented was for SDGR (SCHRODINGER) at 3/2/2020. The price target of $43 was fulfilled within 1 day with a profit of $1.75 (3.91%) receiving and performance score of 39.11.

Average potential price target upside

AKBA Akebia Ther ALNY Alnylam Pharmaceuticals ARQT Arcutis Biotherapeutics  ASND Ascendis Pharma AS BPMC Blueprint Medicines Corp GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals IRWD Ironwood Pharmaceuticals KPTI Karyopharm Therapeutics MGNX MacroGenics RYTM Rhythm Pharmaceuticals SDGR Schrodinger SNDX Syndax Pharmaceuticals ZEAL Zealand Pharma A/S ADR AVRO AVROBIO IMRX Immuneering Corp EPZM Epizyme MIRM Mirum Pharmaceuticals NTLA Intellia Therapeutics PLRX Pliant Therapeutics  NBRV Nabriva Therapeutics AG BMRN Biomarin Pharmaceutical BBIO BridgeBio Pharma COGT Cogent Biosciences PTCT PTC Therapeutics INCY yte

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

6

$4.85 (421.74%)

5

1 months 21 days ago

13/24 (54.17%)

$4.17 (227.87%)

277

Buy

4

$2.85 (247.83%)

2

11 months 18 days ago

1/11 (9.09%)

$2.96 (284.62%)

721

Buy

1

$-0.15 (-13.04%)

8

2 years 1 months 18 days ago

1/2 (50%)

$0.33 (49.25%)

311

Hold

2

$0.85 (73.91%)

6

2 years 1 months 18 days ago

3/11 (27.27%)

$1.28 (177.78%)

467

Buy

6

2 years 1 months 18 days ago

0/3 (0%)

$3.28 (120.59%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Lebowitz is most bullish on?

Potential upside of $77.6 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is David Lebowitz is most reserved on?

Potential downside of -$28.96 has been obtained for BPMC (BLUEPRINT MEDICINES CORP)

What Year was the first public recommendation made by David Lebowitz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?